JP2020533296A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533296A5
JP2020533296A5 JP2020513603A JP2020513603A JP2020533296A5 JP 2020533296 A5 JP2020533296 A5 JP 2020533296A5 JP 2020513603 A JP2020513603 A JP 2020513603A JP 2020513603 A JP2020513603 A JP 2020513603A JP 2020533296 A5 JP2020533296 A5 JP 2020533296A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
predopidine
levodopa
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020513603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533296A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/048920 external-priority patent/WO2019050775A1/en
Publication of JP2020533296A publication Critical patent/JP2020533296A/ja
Publication of JP2020533296A5 publication Critical patent/JP2020533296A5/ja
Pending legal-status Critical Current

Links

JP2020513603A 2017-09-08 2018-08-30 薬物誘発性ジスキネジアを治療するためのプリドピジン Pending JP2020533296A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762556314P 2017-09-08 2017-09-08
US62/556,314 2017-09-08
US201862649184P 2018-03-28 2018-03-28
US62/649,184 2018-03-28
PCT/US2018/048920 WO2019050775A1 (en) 2017-09-08 2018-08-30 PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT

Publications (2)

Publication Number Publication Date
JP2020533296A JP2020533296A (ja) 2020-11-19
JP2020533296A5 true JP2020533296A5 (https=) 2021-03-04

Family

ID=63684481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020513603A Pending JP2020533296A (ja) 2017-09-08 2018-08-30 薬物誘発性ジスキネジアを治療するためのプリドピジン

Country Status (10)

Country Link
US (2) US20190231768A1 (https=)
EP (1) EP3678664A1 (https=)
JP (1) JP2020533296A (https=)
CN (1) CN111343982A (https=)
AU (1) AU2018329628B2 (https=)
BR (1) BR112020004622A2 (https=)
CA (1) CA3075020C (https=)
IL (1) IL273044A (https=)
MX (1) MX383462B (https=)
WO (1) WO2019050775A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
KR102906269B1 (ko) 2023-08-03 2026-01-02 재단법인대구경북과학기술원 파킨슨 환자의 lid 발병 예측을 위한 정보제공방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
SI2146961T1 (sl) 2007-04-12 2014-08-29 IVAX International GmbH N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov
US20100197712A1 (en) 2007-06-18 2010-08-05 Arvid Carlsson Use of dopamine stabilizers
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
HK1206297A1 (en) * 2012-04-04 2016-01-08 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
DK177976B8 (en) 2013-07-10 2021-04-22 Jasopels As Apparatus and method for stretching a pelt on a pelt board
PE20161220A1 (es) 2014-01-22 2016-11-23 Teva Pharmaceuticals Int Gmbh Formulaciones de pridopidina de liberacion modificada
KR102166879B1 (ko) 2014-03-10 2020-10-16 어플라이드 머티어리얼스, 인코포레이티드 다중 하전-입자 빔 리소그래피를 위한 픽셀 블렌딩
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
HRP20251431T1 (hr) 2017-08-14 2026-01-02 Prilenia Neurotherapeutics Ltd. Liječenje amiotrofične lateralne skleroze pridopidinom
EP3675830A1 (en) * 2017-08-30 2020-07-08 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
DE102018204527A1 (de) 2017-09-18 2019-03-21 SEs Solutions GmbH Dachhalterung für ein Automobil

Similar Documents

Publication Publication Date Title
JP2020533296A5 (https=)
FI2629097T1 (fi) Nrf2-seulontatestejä ja niihin liittyviä menetelmiä ja koostumuksia
JP2010518122A5 (https=)
JP2019503365A5 (https=)
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
AU2012284627A8 (en) Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans
JP2013529665A5 (https=)
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
JP2018527305A5 (https=)
JP2018500300A (ja) パーキンソン病を遅延させるための医薬
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
JP2019218379A5 (https=)
JP2016530238A5 (https=)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JP2014520856A5 (https=)
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
JP2020509072A5 (https=)
JP2016528171A5 (https=)
JP2019507786A5 (https=)
JP2020531543A5 (https=)
TWI833874B (zh) 神經變性疾病之預防或治療藥
EP3215222A1 (en) Methods of treating huntington's disease using cysteamine compositions
JP2019535830A5 (https=)